Andera Partners Leads $20 Million Series D Financing in Rivermark Medical

Andera Partners announced it led a $20 million Series D financing in Rivermark Medical, a company focused on innovative treatments for benign prostatic hyperplasia (BPH). The funding will support ongoing clinical trials and prepare for the launch of Rivermark’s FloStent™ System, a non-surgical and fully reversible therapy for BPH.